Science
Approved in one country, unstudied in most others — a framework for reading asymmetric evidence.
Selank and Semax hold genuine regulatory approvals — in Russia, based on domestic clinical programs largely unavailable in translated, peer-reviewed form. That asymmetry defines how they should be evaluated: not as unknown compounds, but as compounds whose evidence cannot be independently audited.
Both are also stability-fragile in ways the gray market routinely ignores; Semax in particular requires cold-chain handling that our shipping-condition testing suggests is rarely maintained.
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchAngiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceLyophilized peptides are more fragile than the marketing suggests. What degradation looks like in our testing data.
Lab InsightsThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
